Advertisement

Medical Oncology

, Volume 20, Issue 3, pp 283–290 | Cite as

Etanercept therapy in patients with advanced primary amyloidosis

  • M. A. HusseinEmail author
  • J. V. Juturi
  • L. Rybicki
  • S. Lutton
  • B. R. Murphy
  • M. A. Karam
Original Article

Abstract

No effective treatment exists for primary amyloidosis, a plasma cell dyscrasia characterized by deposition of amyloid fibrils consisting of monoclonal light chains in various organs. TNF-α has been implicated in other amyloid disorders; therefore, we used etanercept to treat patients with advanced amyloidosis who had failed other therapies or were ineligible for other treatment regimens. Sixteen patients with amyloidosis that included patients with severe cardiac or multiple organ involvement were treated with etanercept and evaluated every 4–6 wk for evidence of toxicity and clinical response. Patients were treated with etanercept for a median of 42 wk. Eight of 16 patients (50%) experienced objective improvements and 14 patients (88%) experienced subjective improvements in symptoms. Only one patient experienced an adverse effect attributable to etanercept. For the entire group, improvement in performance status was statistically significant (p=0.001), estimated median survival is 24.2 mo, 8 of whom are still alive with a median survival is 26.6 mo. The 12 patients with any cardiac involvement had an estimated median survival of 24.2 mo. Six of those 12 patients are still alive, with a median survival is 26.6 mo. The group of eight patients with severe cardiac involvement showed an estimated median survival of 13.2 mo, three of whom are still alive with a median survival is 25.9 mo.

The clinical observations in this group of advanced and relapsed/refractory patients are highly encouraging. For the group as a whole, median survival was 24.2 mo and improvement in performance status was highly significant. Median survival for the patients with severe cardiac involvement was 13.2 mo with 3/8 patients are alive with a median survival of 25+ mo. Moreover, there was a statistically significant improvement in patients’ performance status. These results, even though in a small group of patients, suggest that etanercept may provide a new therapeutic option for the management of amyloidosis that should be studied further.

Key Words

Amyloidosis plasma cell dyscrasias tumor necrosis factor TNF-alpha soluble tumor necrosis factor receptor etanercept 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gertz M, Kyle R. Primary systemic amyloidosis—a diagnostic primer. Mayo Clinic Proceedings 1989; 64:1505–1519.PubMedGoogle Scholar
  2. 2.
    Kyle R, Gertz M. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Sem Hematol 1995; 32:45–59.Google Scholar
  3. 3.
    Kyle R, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992; 79:1817–1822.PubMedGoogle Scholar
  4. 4.
    Gertz M, et al. Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis. Med Oncol 1999; 16:104–109.PubMedGoogle Scholar
  5. 5.
    Gertz M, et al. Phase II trial of high-dose dexamethasone for previously treated immunoglobulin light-chain amyloidosis. Am J Hematol 1999; 61:115–119.PubMedCrossRefGoogle Scholar
  6. 6.
    Kyle R, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336:1202–1207.PubMedCrossRefGoogle Scholar
  7. 7.
    Kyle R, et al. Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood 1999; 93:1062–1066.PubMedGoogle Scholar
  8. 8.
    Gertz M, Kyle R, Greipp P. Response rates and survival in primary systemic amyloidosis. Blood 1991; 77:257–262.PubMedGoogle Scholar
  9. 9.
    Kyle R, Greipp P, Garton J, Gertz M. Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine. Am J Med 1985; 79:708–716.PubMedCrossRefGoogle Scholar
  10. 10.
    Merlini G. Treatment of primary amyloidosis. Sem Hematol 1995; 32:60–79.Google Scholar
  11. 11.
    Cacoub P, et al. Amyloidosis and cardiac involvement. Ann Med Int 2000; 151:611–617.Google Scholar
  12. 12.
    Filella X, et al. Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma. Cancer Det Prevention 1996; 20:52–56.Google Scholar
  13. 13.
    Thavasu P, et al. Multiple myeloma: an immunoclinical study of disease and response to treatment. Hematol Oncol 1995; 13:69–82.PubMedCrossRefGoogle Scholar
  14. 14.
    Shibasaki T, et al. A case of renal amyloidosis associated with hepatic adenoma: the pathogenic role of tumor necrosis factor-alpha. Nephron 1997; 73:350–353.CrossRefGoogle Scholar
  15. 15.
    Rysava R, Merta M, Tesar V, Jirsa M, Zima T. Can serum amyloid A or macrophage colony stimulating factor serve as marker of amyloid formation process? Biochem Mol Biol Internatl 1999; 47:845–850.Google Scholar
  16. 16.
    Husebekk A, Stenstad T. Experimental AA-amyloidosis in mice is inhibited by treatment with the anti-rheumatic drug tenidap. Scand J Immunol 1996; 43:551–555.PubMedCrossRefGoogle Scholar
  17. 17.
    Charles P, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999; 163:1521–1528.PubMedGoogle Scholar
  18. 18.
    Nakashima Y, Akizawa T, Nagai T, Koshikawa S. Role of uremic and endothelial factors in the development of beta 2-microglobulin amyloidosis. Kidney Internatl-Suppl 1993; 41:S88-S95.Google Scholar
  19. 19.
    Blasko I, Schmitt T, Steiner E, Trieb K, Grubeck-Loebenstein B. Tumor necrosis factor alpha augments amyloid beta protein (25–35) induced apoptosis in human cells. Neurosci Lett 1997; 238:17–20.PubMedCrossRefGoogle Scholar
  20. 20.
    Sutton E, et al. Amyloid-beta peptide induced inflammatory reaction is mediated by the cytokines tumor necrosis factor and interleukin-1. J Submicrosc Cytol Pathol 1999; 31:313–323.PubMedGoogle Scholar
  21. 21.
    McDermott M, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97:133–144.PubMedCrossRefGoogle Scholar
  22. 22.
    Jadoul M, et al. Autosomal-dominant periodic fever with AA amyloidosis: Novel mutation in tumor necrosis factor receptor 1 gene. Kidney Internatl 2001; 59:1677–1682.CrossRefGoogle Scholar
  23. 23.
    Aksentijevich I, et al. The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in tnfrsf1a, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Human Genet 2001; 69:301–314.CrossRefGoogle Scholar
  24. 24.
    Galon J, Aksentijevich I, McDermott M, O’Shea J, Kastner D. TNFRSF1A mutations and autoinflammatory syndromes. Curr Opin Immunol 2000; 12:479–486.PubMedCrossRefGoogle Scholar
  25. 25.
    Mohler K, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993; 151:1548–1561.PubMedGoogle Scholar
  26. 26.
    Comenzo R, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998; 91:3662–3670.PubMedGoogle Scholar
  27. 27.
    Moreland L, et al. Longterm safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001; 28:1238–1244.PubMedGoogle Scholar

Copyright information

© Humana Press Inc 2003

Authors and Affiliations

  • M. A. Hussein
    • 1
    Email author
  • J. V. Juturi
    • 1
  • L. Rybicki
    • 2
  • S. Lutton
    • 3
  • B. R. Murphy
    • 4
  • M. A. Karam
    • 1
  1. 1.Multiple Myeloma Research ProgramThe Cleveland Clinic FoundationClevelandUnited States of America
  2. 2.Department of Cancer Center BiostatisticsThe Cleveland Clinic FoundationClevelandUnited States of America
  3. 3.Department of CardiologyThe Cleveland Clinic FoundationClevelandUnited States of America
  4. 4.Sandusky InternistsSanduskyUnited States of America

Personalised recommendations